SeromYx combines an extensive suite of biophysical interaction assays and primary cell–based functional assays to characterize the full spectrum of Fc-mediated antibody activity.
Our platform connects Fc structure to immune function, enabling teams to understand mechanism of action (MoA) and make informed development decisions.
Assays are performed in scalable 96–384-well formats and can process thousands of samples per run. We support human, non-human primate (NHP), and murine systems, with additional species available upon request.
BIOPHYSICAL ASSAYS
Fc Receptor Binding Array
Fluorescently coded microspheres capture multiple antigen specificities simultaneously and profile the effector capacity by assessing interaction of antigen-specific antibodies with Fc receptors.
Available receptors: FCGR2A (R131, H131), FCGR2B, FCGR3A (V158, F158), FCGR3B, FCRN (pH 6.0, 7.4), FCA, C1q, TRIM21.
Antigen Specific Antibody Isotyping and Subclassing (ISSC)
Fluorescently coded microspheres capture multiple antigen specificities simultaneously and profile the isotype/subclass distribution in an antigen-specific manner.
Available detectors: Total IgG, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgE.
Antibody Avidity by SPR
Avidity Index measures the strength of binding to a target antigen by either polyclonal antibodies from serum or monoclonal antibody cocktails. The off-rate is utilized along with the magnitude of response to compute avidity index.
Antibody Affinity by SPR
Tripartite binding measures traditional antibody affinity kinetics in an antigen-specific manner. The kinetics of the antigen-antibody-receptor interaction describe the on-rate, the off-rate, and the associated affinity (equilibrium dissociation constant, KD) of the antibody with the receptor. We also conduct bipartite Fc-FcR affinity measurements.
CELLULAR FUNCTIONAL ASSAYS
Antibody Dependent Cellular Phagocytosis (ADCP)
Assesses the ability of antibodies to induce phagocytosis of antigen- functionalized fluorescent beads by monocytes via Fc receptors.
Antibody Dependent Cellular Cytotoxicity (ADCC)
Tests the ability of antigen-specific antibodies to recruit NK cell lytic activity.
Complement Dependent Cytotoxicity (CDC)
Tests the ability of antigen-specific antibodies to activate complement-mediated cell death.
Antibody Dependent NK Cell Activation (ADNKA)
Assesses the ability of antibodies to induce NK cell activation against antigen-coated plates by measuring the levels of CD107a, IFN-γ and MIP-1β.
Antibody Dependent Neutrophil Phagocytosis (ADNP)
Assesses the ability of antibodies to induce the phagocytosis of antigen-coated targets by primary neutrophils.
Antibody Dependent Basophil Phagocytosis (ADBP)
Assesses the ability of antibodies to induce the phagocytosis of antigen-coated targets by primary basophils.
Antibody Dependent Eosinophil Phagocytosis (ADEP)
Assesses the ability of antibodies to induce the phagocytosis of antigen-coated targets by primary eosinophils.
Antibody Dependent Dendritic Cell Phagocytosis (ADDCP)
Assesses the ability of antibodies to induce phagocytosis of antigen-coated targets by dendritic cells as well as DC activation/maturation and cytokine release.
Antibody Dependent Cellular Deposition (ADCD)
Assesses the recruitment of complement component C3b on the surface of antigen-coupled beads.
Antibody Dependent Mucin Binding (ADMB)
Measures the capacity of antibodies to trap pathogens in mucus proteins.
Antibody Dependent Enhancement of Infection (ADEI)
Measures the enhancement of viral infection caused by antigen specific antibodies in non-susceptible target cells.
Frequently Asked Questions (FAQ)
What is Systems Serology?
Systems Serology is a systems-level immune profiling approach that combines Fc effector function assays, Fc receptor binding measurements, and computational analytics to define how antibodies function, not just what they bind.
How is SeromYx different from other CROs?
Most CROs offer Fc assays as part of a broader service menu.
SeromYx is built entirely around Fc biology.
Our scientific team specializes in understanding how antibody structure, subclass, and receptor engagement translate into functional immune outcomes. That depth allows us to design smarter studies, ask better mechanistic questions, and generate data that meaningfully informs development decisions.
Do you support both vaccines and antibody therapeutics?
Yes. We support both vaccine and antibody therapeutic developers across discovery, preclinical, and clinical stages.
- For vaccines, we help define functional correlates of protection and immune durability.
- For antibody therapeutics, we characterize Fc-driven mechanisms of action, safety signals, and engineering outcomes.
